CARMAT
1 known investors
CARMAT develops Aeson, a total artificial heart that replaces both ventricles to treat patients with end-stage biventricular heart failure. The device is commercially available as a bridge to transplant in the European Union and countries recognizing CE marking, and is under an Early Feasibility Study in the United States.
BiotechHealthtechMedical Devices
Investors · 1
Frequently asked questions
- What does CARMAT do?
- CARMAT develops Aeson, a total artificial heart that replaces both ventricles to treat patients with end-stage biventricular heart failure. The device is commercially available as a bridge to transplant in the European Union and countries recognizing CE marking, and is under an Early Feasibility Study in the United States.
- Who are CARMAT's investors?
- CARMAT's investors include Air Liquide Venture Capital (ALIAD).